resensitizing daclatasvir-resistant hepatitis c variants allosteric modulation ns5a
estimated million people infected hepatitis c virus hcv worldwide clinical trials demonstrated first time human history potential exists eradicate chronic viral disease using combination therapies contain direct-acting antiviral agents hcv nonstructural protein 5a ns5a multifunctional protein required several stages virus replication cycle ns5a replication complex inhibitors exemplified daclatasvir dcv also known bms daklinza belong potent class direct-acting anti-hcv agents described far vitro activity picomolar pm low nanomolar nm range potency observed vitro translated clinical efficacy hcv rna declining similar log infected patients administration single oral doses dcv understanding exceptional potency dcv key objective study show although dcv ns5a inhibitor analogue syn- inactive certain ns5a resistance variants combinations pair enhance dcv potency >-fold restoring activity pm range synergistic effect validated vivo using hcv-infected chimaeric mouse model cooperative interaction pair compounds suggests ns5a protein molecules communicate other: one inhibitor binds resistant ns5a causing conformational change transmitted adjacent ns5as resensitizing resistant ns5a second inhibitor can act restore inhibition unprecedented synergistic anti-hcv activity also enhances resistance barrier dcv providing additional options hcv combination therapy new insight role ns5a hcv replication cycle
